Immediate Impact
63 standout
Citing Papers
Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
2024 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
Works of Aflah Roohullah being referenced
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
2018
A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Aflah Roohullah | 130 | 17 | 28 | 59 | 49 | 20 | 230 | |
| Iago De Castro Silva | 146 | 23 | 14 | 76 | 76 | 16 | 211 | |
| Yu Chen | 139 | 26 | 33 | 58 | 106 | 21 | 272 | |
| Chen Liu | 79 | 10 | 18 | 30 | 109 | 19 | 219 | |
| Hadi Nasiri | 95 | 11 | 14 | 52 | 119 | 18 | 255 | |
| Teresa Troiani | 107 | 15 | 37 | 18 | 30 | 19 | 156 | |
| Marisol Miranda Galvis | 131 | 43 | 47 | 67 | 83 | 25 | 285 | |
| Natalia Sauer | 111 | 13 | 30 | 98 | 83 | 28 | 281 | |
| Yao Sun | 78 | 12 | 22 | 45 | 72 | 13 | 256 | |
| Jesus C. Fabregas | 121 | 35 | 43 | 52 | 73 | 21 | 228 | |
| Lindsey Carlsen | 121 | 6 | 36 | 55 | 115 | 20 | 250 |
All Works
Login with ORCID to disown or claim papers
Loading papers...